TWST: Twist Bioscience’s Q2 FY2026 Revenue Climbs, Margins Expand, and Guidance Lifts The Curtain on a Profitability Path

Numbers at a glance

The quarter ended March 31, 2026 produced $110.7 million in total revenue, up 19% from $92.8 million in the year-ago period. Gross margin rose to 51.6% from 49.6% a year earlier. Cost of revenues totaled $53.6 million versus $46.8 million in the prior year.

Segment detail tells the story behind the top line: DSPS generated $53.3 million (up 28% YoY and +4% sequentially), while NGS Applications contributed $57.4 million (up 12% YoY and +9% sequentially).

Margins, costs, and the profitability path

Gross margin improvement to 51.6% reflects a favorable mix and operating leverage, with management signaling a target above 52% for the full year. Cost of revenues rose year over year as the company scales its core platforms.

Research and development expenses for the quarter declined to $19.7 million from $23.9 million in the prior-year period, suggesting some near-term cost discipline as growth accelerates.

Guidance and the earnings narrative

Twist lifted its revenue forecast for fiscal 2026 to a range of $442–$447 million. Management reiterated a plan to achieve adjusted EBITDA breakeven in Q4 FY26, with a target gross margin staying above 52% for the year. This setup emphasizes cash profitability over a reported EPS figure in the near term, which means the earnings surprise angle will hinge on how the company translates top-line momentum and margin gains into earnings per share in subsequent quarters. For now, there is no explicit EPS number disclosed in the release, so the market will be watching the ellipse between revenue growth and earnings results.

Executive commentary and strategic read

CEO Emily M. Leproust, Ph.D., emphasized a continued growth trajectory, noting the thirteenth consecutive quarter of growth and revenue beating guidance. The narrative centers on scaling DNA Synthesis and Protein Solutions (DSPS) along with NGS applications, while steering the business toward profitability. With adj. EBITDA as the near-term profitability metric, Twist’s strategy mirrors a broader pattern in biotech tooling: push volume and mix higher, then optimize the cost structure to convert growth into earnings power.

Implications for TWST and sector peers

Twist’s quarter underscores demand resilience across its DSPS and NGS portfolios, with growth in both segments and an improving margin backdrop. If the company sustains a gross margin near or above the 52% target and advances toward adj. EBITDA breakeven, it supports a constructive read on the stock and might influence how investors calibrate earnings potential for similar mid-cap biotech tooling names. For peers, the takeaway is a reminder that revenue growth alone isn’t enough—margin discipline and a clear path to profitability matter when the EPS consensus and potential earnings surprise become material in future quarters.

Bottom line

Twist Bioscience’s Q2 FY2026 results present a coherent narrative: top-line momentum, margin expansion, and a clear path to profitability via adj. EBITDA breakeven in Q4 FY26. The absence of an immediate GAAP EPS figure means the EPS storyline remains to be written in future releases, but the revenue forecast upgrade and the margin trajectory offer a framework for evaluating TWST against its sector peers. The question for investors is whether Twist can sustain this rhythm long enough to translate growth into durable earnings power and a meaningful earnings surprise once GAAP reporting catches up with the narrative.